IS3412A7 - Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum - Google Patents

Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum

Info

Publication number
IS3412A7
IS3412A7 IS3412A IS3412A IS3412A7 IS 3412 A7 IS3412 A7 IS 3412A7 IS 3412 A IS3412 A IS 3412A IS 3412 A IS3412 A IS 3412A IS 3412 A7 IS3412 A7 IS 3412A7
Authority
IS
Iceland
Prior art keywords
analogue method
cytidine derivatives
producing cytidine
producing
derivatives
Prior art date
Application number
IS3412A
Other languages
English (en)
Other versions
IS1895B (is
Inventor
Fujiu Morio
Ishitsuka Hideo
Miwa Masanori
Umeda Isao
Yokose Kazutera
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of IS3412A7 publication Critical patent/IS3412A7/is
Publication of IS1895B publication Critical patent/IS1895B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
IS3412A 1987-11-17 1988-11-16 Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum IS1895B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17

Publications (2)

Publication Number Publication Date
IS3412A7 true IS3412A7 (is) 1989-05-18
IS1895B IS1895B (is) 2003-10-20

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3412A IS1895B (is) 1987-11-17 1988-11-16 Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum

Country Status (35)

Country Link
US (1) US4966891A (is)
EP (1) EP0316704B1 (is)
JP (1) JPH0678350B2 (is)
KR (1) KR970000241B1 (is)
CN (1) CN1022688C (is)
AR (1) AR247217A1 (is)
AT (1) ATE124951T1 (is)
AU (1) AU619220B2 (is)
CA (1) CA1327358C (is)
CS (1) CS274486B2 (is)
DE (2) DE10199027I2 (is)
DK (1) DK170893B1 (is)
DZ (1) DZ1270A1 (is)
ES (1) ES2074429T3 (is)
FI (1) FI89804C (is)
GR (1) GR3017686T3 (is)
HK (1) HK1003114A1 (is)
HU (1) HU199866B (is)
IE (1) IE883430L (is)
IL (1) IL88363A0 (is)
IS (1) IS1895B (is)
LT (1) LT2185B (is)
LU (1) LU90769I2 (is)
LV (1) LV5624A3 (is)
MC (1) MC1992A1 (is)
MX (1) MX173347B (is)
NL (1) NL300045I2 (is)
NO (2) NO171167C (is)
NZ (1) NZ226923A (is)
PH (1) PH25641A (is)
PT (1) PT89009B (is)
SU (1) SU1736342A3 (is)
UA (1) UA19333A (is)
YU (1) YU47122B (is)
ZA (1) ZA888428B (is)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
TW254946B (is) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1631278A4 (en) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
DE602004015331D1 (de) * 2003-12-22 2008-09-04 Hoffmann La Roche Verfahren für fluorcytidinderivate
US20080312207A1 (en) * 2004-02-18 2008-12-18 Craig Johnstone Compounds
DE602005013491D1 (de) * 2004-02-18 2009-05-07 Astrazeneca Ab Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
EP1868608A2 (en) * 2005-04-01 2007-12-26 F. Hoffmann-Roche AG Method for administration of capecitabine
JP2008542247A (ja) * 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ グルコキナーゼモジュレーターとしての２−フェニル置換イミダゾール［４，５ｂ］ピリジン／ピラジンおよびプリン誘導体
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
JP2009500442A (ja) * 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
CA2614746C (en) 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
JP2009501734A (ja) * 2005-07-21 2009-01-22 ヌボ・リサーチ・インコーポレイテッド 癌の治療方法
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
TW200833339A (en) 2006-12-21 2008-08-16 Astrazeneca Ab Novel crystalline compound
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
WO2008131062A2 (en) * 2007-04-20 2008-10-30 Dr. Reddy's Laboratories Ltd. Process for preparing capecitabine
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2225566A1 (en) * 2008-01-03 2010-09-08 Plus Chemicals S.A. Process for the preparation of capecitabine
ES2958968T3 (es) 2008-06-17 2024-02-16 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CA2732165A1 (en) 2008-08-04 2010-02-11 Astrazeneca Ab Therapeutic agents 414
SI2326329T1 (sl) * 2008-08-04 2017-06-30 Wyeth Llc Antineoplastične kombinacije 4-anilino-3-cianakinolinov in kapecitabina
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
WO2010117633A1 (en) 2009-04-06 2010-10-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
US20110021769A1 (en) * 2009-07-23 2011-01-27 Scinopharm Taiwan Ltd. Process for Producing Fluorocytidine Derivatives
ES2584433T3 (es) 2010-03-12 2016-09-27 Genzyme Corporation Terapia de combinación para tratar cáncer de mama
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9328106B2 (en) 2012-09-26 2016-05-03 Genentech, Inc. Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
CA2890359A1 (en) * 2012-11-07 2014-05-15 Zucai SUO Substituted gemcitabine aryl amide analogs and treatment methods using same
CN105792830A (zh) * 2013-03-15 2016-07-20 Z·索 取代的吉西他滨双环酰胺类似物和使用其的治疗方法
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
SG11201810947PA (en) * 2016-06-28 2019-01-30 Cellix Bio Private Ltd Compositions and methods for the treatment of cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN110831605A (zh) 2017-04-26 2020-02-21 托马斯·I.·卡尔曼 多靶标的核苷衍生物
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN111801339A (zh) * 2018-01-19 2020-10-20 纽科利制药公司 5-氟尿嘧啶化合物
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
SG11202100411TA (en) * 2018-08-03 2021-02-25 Cellix Bio Private Ltd Compositions and methods for the treatment of cancer
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
EP4185274A1 (en) 2020-07-24 2023-05-31 Strand Therapeutics Inc. Lipidnanoparticle comprising modified nucleotides
TW202241931A (zh) 2021-01-08 2022-11-01 美商斯特蘭德治療股份有限公司 表現構築體及其用途
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
NO885106D0 (no) 1988-11-16
HUT48267A (en) 1989-05-29
DZ1270A1 (fr) 2004-09-13
MX173347B (es) 1994-01-03
DK640388A (da) 1989-05-18
DK640388D0 (da) 1988-11-16
LT2185B (lt) 1993-10-15
GR3017686T3 (en) 1996-01-31
CS274486B2 (en) 1991-04-11
US4966891A (en) 1990-10-30
FI89804C (fi) 1993-11-25
FI885329A (fi) 1989-05-18
NL300045I1 (nl) 2001-08-01
EP0316704A2 (de) 1989-05-24
JPH01153696A (ja) 1989-06-15
EP0316704A3 (en) 1990-11-22
HU199866B (en) 1990-03-28
YU47122B (sh) 1994-12-28
DE3854148D1 (de) 1995-08-17
CN1033183A (zh) 1989-05-31
SU1736342A3 (ru) 1992-05-23
NO171167C (no) 1993-02-03
EP0316704B1 (de) 1995-07-12
CN1022688C (zh) 1993-11-10
JPH0678350B2 (ja) 1994-10-05
CS747588A2 (en) 1990-09-12
NO171167B (no) 1992-10-26
KR970000241B1 (ko) 1997-01-08
HK1003114A1 (en) 1998-10-09
UA19333A (uk) 1997-12-25
NL300045I2 (nl) 2002-01-02
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
IE883430L (en) 1989-05-17
MX13836A (es) 1993-10-01
NO885106L (no) 1989-05-18
AU619220B2 (en) 1992-01-23
DK170893B1 (da) 1996-03-04
YU209188A (en) 1990-08-31
DE10199027I1 (de) 2001-08-02
AU2516888A (en) 1989-05-25
PH25641A (en) 1991-08-21
IS1895B (is) 2003-10-20
CA1327358C (en) 1994-03-01
FI89804B (fi) 1993-08-13
PT89009A (pt) 1988-12-01
ATE124951T1 (de) 1995-07-15
PT89009B (pt) 1993-02-26
LU90769I2 (fr) 2001-07-02
IL88363A0 (en) 1989-06-30
NZ226923A (en) 1990-10-26
ES2074429T3 (es) 1995-09-16
FI885329A0 (fi) 1988-11-17
KR890008162A (ko) 1989-07-10
DE10199027I2 (de) 2002-01-31
NO2001013I2 (no) 2006-05-01
AR247217A1 (es) 1994-11-30
ZA888428B (en) 1989-06-28

Similar Documents

Publication Publication Date Title
IS1895B (is) Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum
PT88596A (pt) Process for preparing 2-anilinopyrimidine derivatives useful aspesticidas
PT87603A (pt) Process for preparing alkoxy-substituted dihydrobenzopyran-2-caboxylate derivatives
PT86660A (pt) Process for preparing adenosine 5:-carboxamide derivatives
PT87014A (pt) Method for producing ibuprofen
DK507188D0 (da) Cholecalciferolderivater
KR890701199A (ko) 기체 조절방법
DK378088A (da) Alkenderivater
KR880001562A (ko) 알킬페놀류의 제조방법
DK49688A (da) Propiolophenonderivater
KR870001175A (ko) 5-치환된-6-아미노피리미딘 유도체의 제조방법
FI902772A0 (fi) Menetelmä puutuotteiden valmistamiseksi
BR8801041A (pt) Metodo pesticida utilizando derivados de 2-fenil-imidazol
KR860004919A (ko) 뉴클레오시드 유도체의 제조방법
KR890010537A (ko) 어라인먼트방법
KR900700430A (ko) 알킬 3-알콕시프로피오네이트의 제조방법
DK271088D0 (da) Tienopyridinderivater
DK358288D0 (da) Fremgangsmaade til fremstilling af 2-arylthiobenzoesyrer
KR900007855A (ko) N-포스포노메틸글리신의 제조 방법
DK695788A (da) Naphtalenderivater
NO903496L (no) Fremgangsmaate for metanomdanning.
KR900009594A (ko) 2-클로로-5-클로로메틸피리딘의 제조방법
PT86829A (pt) Process for preparing thienothiopyran derivatives
PT88407A (pt) Process for preparing azolidinedione derivatives
FI914767A0 (fi) Menetelmä nukleosidijohdannaisten valmistamiseksi